Vertex’s Telaprevir Excels in Treatment-Experienced HCV Population

Boosting its chances of approval, Vertex’s telaprevir showed a 65 percent viral cure rate among the hardest-to-treat hepatitis C (HCV) patients, the company announced Tuesday. With the news, telaprevir and Merck’s competing boceprevir are both on pace for approval sometime next year. Both Merck, which released positive Phase III results in a same treatment-failure population last month for boceprevir, and Vertex expect to have their NDAs completed and submitted to the FDA by year’s end.
Drug Industry Daily